Chrontropic incompetence can limit exercise tolerance in COPD patients with lung hyperinflation

Sébastien Hulo1
Jocelyn Inamo2
Aurélie Dehon3
Olivier Le Rouzic4
Jean-Louis Edme1
Remi Neviere5

1Université Lille, CHU Lille, EA 4483, IMPact de l’Environnement Chimique sur la Santé humaine, Lille, France;
2Département de Cardiologie – CHU Fort de France, Martinique – Faculté de Médecine – Université des Antilles, France;
Pôle d’Anesthésie Réanimation ADRU, CHU Nimes, Nimes, France;
3Université Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Lille, France;
4Université Lille, Inserm, CHU Lille, Lille Inflammation Research International Center, Lille, France

Correspondence: Sébastien Hulo
Université de Lille – IMPECS – IMPact de l’Environnement Chimique sur la Santé Humaine (EA 4483), Faculté de Médecine de Lille – Pôle Recherche – 2nd Étage Aile EST 1, Place Verdun 59045 Lille Cedex, France
Tel +33 320 627 761
Fax +33 320 627 784
Email sebastien.hulo@univ-lille2.fr

Purpose: Metabolic-chronotropic relationship is the only concept that assesses the entire chrontropic function during exercise, as it takes into account individual fitness. To better understand interrelationships between chrontropic incompetence (CI), dynamic hyperinflation (DH) and exercise limitation among Global initiative for chronic Obstructive Lung Disease (GOLD) stages of chronic obstructive pulmonary disease (COPD) disease severity, we evaluated cardiopulmonary responses to symptom-limited cycle exercise in stable patients.

Patients and methods: We prospectively studied 47 COPD patients classified by GOLD stage severity. Pulmonary function tests and cardiopulmonary responses to symptom-limited incremental exercise were studied. CI was defined by regression line between percent heart rate (HR) reserve and percent oxygen uptake ($V_{O2}$) reserve, ie, chrontropic-metabolic index (CMI). DH was defined from the knot resulting from the nonlinear regressions of inspiratory capacity changes from rest to peak (dynamic inspiratory capacity (ICdyn)) with percentage of maximal HR and CMI.

Results: Aerobic capacity (median interquartile ranges) peak $V_{O2}$, 24.3 (23.6; 25.2), 18.5 (15.5; 21.8), 17.5 (15.4; 19.1) mL·kg$^{-1}$·min$^{-1}$ and CMI worsened according to GOLD severity. The optimal knot of ICdyn was equal to −0.34 L. The multivariate logistic regression showed a strong relationship between CI (outcome) and DH (odds ratio [confidence interval 95%]) 25 (3.5; 191.6).

Conclusion: COPD patients with DH have a poor cardiovascular response to exercise, which may be attributed to CI.

Keywords: COPD, hyperinflation, chrontropic incompetence, exercise

Introduction

Patients with chronic obstructive pulmonary disease (COPD) have limited exercise tolerance, which has been related to reduced maximal voluntary ventilation (MMV), impaired diffusion capacity of the lung and lung hyperinflation.1–3 The major consequence of lung hyperinflation is the association of increased ventilatory workload and decreased inspiratory muscle pressure generating capacity, which contributes to dyspnea and poor exercise tolerance.3–4 Beyond the lungs, deleterious cardiovascular consequences of dynamic hyperinflation (DH) have been consistently identified in COPD patients during incremental exercise.5–7 In these observations, DH was associated with reduced oxygen ($O_2$) uptake efficiency slope and $O_2$ pulse, which noninvasively reflect cardiac stroke volume during submaximal exercise.5,8,9 Interestingly, lung volume reduction surgery has been shown to improve exercise tolerance through cardiac stroke volume increases.10

Along with cardiac stroke volume impairment is the concept that a contributing factor of reduced cardiac output leading to poor exercise tolerance might be the...
Of note, whether CI as evaluated by CMI was related to lung and powerful outcome predictor in severe COPD patients. Recent findings supported that CI is common in patients with severe COPD and may be improved after lung volume reduction surgery.

Consistent studies have shown that acute lung hyperinflation in breath-hold maneuvers can induce pulmonary vessels and heart compression leading to sympathetic activity increase. It is thus likely that chronic hyperinflation in COPD patients would lead to chronic sympathetic over-activation and blunted cardiac chronotropic response. Recent findings supported that CI is common in patients with severe COPD and may be improved after lung volume reduction surgery. CI was also found as an independent and powerful outcome predictor in severe COPD patients. Of note, whether CI as evaluated by CMI was related to lung hyperinflation has not been reported previously. Our aim was thus to test whether CI could be related to lung DH in exercising patients. We also aimed to determine the different factors, such as breathing pattern, DH and CI, which can influence exercise intolerance in COPD patients.

Patients and methods

Patients

This study was conducted in accordance with the amended Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3). The Institutional Review Board of Lille University Hospital (Lille, France) approved this study (2014-0111-b), which only included patients referred to our department for routine functional evaluation. Written informed consent was obtained from all patients. We prospectively enrolled all consecutive patients suffering from COPD, defined according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The diagnosis of COPD was confirmed by forced spirometry, when the patient was considered clinically stable. All the procedures and their risks were explained to the patients, who gave their verbal informed consent to enter the study. Pulmonary function testing as well as exercise studies had been undertaken for clinical reasons at the request of the patients’ clinicians.

Inclusion and exclusion criteria

Caucasian subjects, either current or former smokers, with spirometrically confirmed COPD in GOLD stages were included. They had to have been free of COPD exacerbations during the last 3 months prior to inclusion. Patients with a history of left ventricular disease, left ventricular ejection fraction <45%, severe pulmonary hypertension (mean pulmonary artery pressure (PAP) >35 mmHg) were excluded. Patients treated for hypertension with blood pressure >160/90 mmHg, with arrhythmias, with significant coronary artery disease or using β-blockers were also excluded. None of the subjects had noninvasive positive-pressure ventilation support or long-term ambulatory O2 treatment.

Pulmonary function

Standard forced expiratory spirometry (forced expiratory volume in the first second (FEV1) and forced expiratory vital capacity (FVC)) and body plethysmography (residual volume (RV), functional residual capacity (FRC), total lung capacity (TLC)), and diffusing capacity of the lung for carbon monoxide (DLCO) were performed (MasterScreen™ body plethysmograph, Viasys, France) using European and American Thoracic Society guidelines.
Cardiopulmonary testing

Cardiopulmonary exercise testing was performed according to standardized procedures using an electromagnetic braked cycle ergometer. Exercise protocol involved an initial 2 minutes of rest, followed by 2 minutes of unloaded cycling with a progressive increment every minutes (10 W·m⁻¹) until exhaustion at a pedaling frequency of 60–65 rpm. Subjects were continuously monitored by 12-lead electrocardiogram (Cardiosoft, CareFusion, France). Blood pressure assessed by sphygmomanometry was recorded every 2 minutes. Arterial blood (240 μL) was sampled at rest and at peak exercise and immediately analyzed using a blood gas analyzer/co-oximeter (ABL700, Radiometer, France).

Subjects respired through an oro-nasal mask (Hans Rudolf 7450 SeriesV2™ Mask, CareFusion, France). Breath-by-breath cardiopulmonary data (Vyntus, CareFusion, France) were measured at rest, warm up and incremental exercise testing. Before each test, O₂ and carbon dioxide (CO₂) analyzers and flow mass sensor were calibrated using available precision gas mixture and a 3-L syringe, respectively. Minute ventilation (V’E), V’O₂, carbon dioxide output (V’CO₂) were recorded as concurrent 10 seconds moving averages, as was determined ventilation anaerobic threshold (AT) by the V-slope method. Ventilatory reserve was calculated as the product of systolic blood pressure by the HR. Peak oxygen pulse (O₂ pulse) was calculated and was expressed in mL per beat and as percentage of predicted value by dividing the predicted peak V’O₂ by predicted peak HR. V’E/V’CO₂ slope was calculated off-line as a linear regression function using 10-s averaged values and excluding the non-linear part of the relationship after the respiratory compensation point (where nonlinear rise in V’E occurred relative to V’CO₂ in the presence of decrease of end-tidal pressure of CO₂). The V’O₂ efficiency slope (OUES) describes the relationship between V’O₂ and V’E during incremental exercise, via a log transformation of V’E. OUES was expressed as the slope of the linear relationship of log₁₀ V’E to V’O₂ (L·min⁻¹) using V’O₂ (L·min⁻¹)=m(log₁₀ V’E)+b, where m=OUES. Double-product (mmHg·bpm) was calculated as the product of systolic blood pressure by the HR.

DH

Changes in operational lung volumes were evaluated from measurements of inspiratory capacity (IC). End-expiratory lung volume (EELV) was assessed from IC maneuvers at rest, every 2 minutes during exercise and at peak exercise (Vyntus). In these maneuvers, after EELV was observed to be stable over 3–4 breaths, subjects were instructed to inspire maximally to TLC. For each measurement, EELV was calculated as resting TLC minus IC, using the plethysmographic TLC value. Dynamic IC (ICdyn) was defined as resting IC minus IC at peak exercise. DH as dichotomous variable was performed from optimal knot of ICdyn (see section “Statistical analysis”, “Results”, and Figure 1).

![Figure 1](image-url) Relationship between dynamic inspiratory capacity (ICdyn) changes from rest to peak with chronotropic-metabolic index and percentage of age-predicted maximum heart rate (HRmax). (A and B), respectively. Notes: Global Initiative for Chronic Obstructive Lung Disease stages (stage 1: half-full dots; stage 2: empty squares; stage 3 and 4: filled triangles). The broken-line trend is represented by the black solid lines.
in tidal volume ($V'_O$) relative to $V'_O$ (expressed as % peak $V'_O$) was determined in each patient during exercise.

**CMI**

Chronotrophic index was defined as an index of maximal predicted HR reserve achieved. The percentage of HR reserve used at peak exercise referred to $[(HR_{age} - HR_{rest})(220 - age in years - HR_{rest})] \times 100$, where $HR$ is heart rate. For any given stage of exercise, the percentage of $V'_O$ reserve used referred to $[(V'_O^{stage} - V'_O^{rest})(V'_O^{peak} - V'_O^{rest})] \times 100$. CMI was calculated off-line as the regression line slope between percent HR reserve and percent $V'_O$ reserve. A patient was referred to as having CI if the resulting slope index was <0.75 and $HR_{max} <80\%$.11,14

**Statistical analysis**

The statistical analyses were performed with SAS software (SAS Institute Inc., Cary, NC, USA; version 9.3). A two-sided significance level of 0.05 was chosen for all tests. Descriptive statistics, with tests of normality (Shapiro–Wilk test) for values showed free distributions. Values were expressed as medians with interquartile ranges (IQR). Patients were divided according to GOLD classification. Nonparametric analysis (Kruskal–Wallis test) was used to test differences between classes. Post hoc comparisons were determined by Wilcoxon test with Bonferroni correction. Relationships between quantitative variables were assessed by the Spearman’s correlation coefficient ($r$). Bivariate comparisons for categorical variables were performed with Chi-squared test (with Fisher correction as appropriate).

Locally estimated scatterplot smoother SAS procedure showed a broken-line trend between CMI or $HR_{max}$, and $IC_{dyn}$ changes. Linear mixed model procedure was used to analyze the change of CMI and $HR_{max}$ versus a broken function of $IC_{dyn}$ that took 0 before the knot and subject’s $IC_{dyn}$ after the knot; the knot position was fixed by the smallest Akaike information criterion (AIC) using Gauss–Newton method.31,32 Thus, mean and 95% confidence interval of optimal knot, intercept (no change), and slope (increase) were estimated by nonlinear mixed model. As these two variables are used interchangeably in the literature to define CI, we took the middle of the overlap area of the $IC_{dyn}$ knot from these two relationships. $IC_{dyn}$ converted to DH as dichotomous variables indicating $IC_{dyn} <$ optimal knot (DH=1) or $IC_{dyn} \geq$ optimal knot (DH=0). The association between CI and DH with covariates (age, body mass index (BMI), TLC, IC/TLC, RV/TLC, GOLD stage) was estimated as an odds ratio (OR) and 95% confidence intervals by using multivariate logistic regression analyses.

**Results**

We included 47 consecutive stable COPD patients (age 55 (49; 61) years, BMI 26 (22; 30), female n=14). All patients were maximally treated with bronchodilators. At study entry, patients were receiving inhaled steroids (75%), long-acting $\beta_2$-agonists (75%) and tiotropium (65%); all of them were active or ex-smokers. Overall, a wide range of airflow obstruction (FEV$_1$/FVC from 26% to 69%; 56 (50; 64) %), static hyperinflation (IC/TLC from 24% to 61% predicted; 40 (36; 46) % predicted), diffusing capacity ($DL_{CO}$ from 17% to 98% predicted; 73 (49; 85) % predicted) was found. Nine out of 42 patients (21%) suffered from well-controlled arterial hypertension and were on diuretics (72%), ACE-inhibitors (52%), calcium-antagonists (36%) to control the disease.

According to objective ATS/ACCP criteria, exercise was considered maximal in all patients. Mean peak workload and $V'_O$ was 90 (65; 95) watts (range 55–170 watts) and 18.5 (15.6; 22.6) mL·kg$^{-1}$·min$^{-1}$ (67 (61; 78) % predicted), respectively. AT $V'_O$ was 12.1 (11.0; 14.4) mL·kg$^{-1}$·min$^{-1}$. Peak $V'_T$ to FEV$_1$ ratio was 37 (30; 48) % and plateau of $V'_T$ increase occurred at 70.8 (61.1; 77.8) % of maximum $V'_E$. Breathing reserve at peak exercise was reduced (24 (3; 33) %). $IC_{dyn}$ change measured from rest to peak exercise was $-0.39$ ($-0.67$; $-0.07$) L and peak EELV (% TLC) was 64 (56; 72) %. $HR_{max}$ was 134 (119; 150) bpm (80 (73; 88) % predicted) with HR reserve utilization of 60 (43; 76) %. Peak O$_2$ pulse was 10.2 (8.6; 12.4) mL·bpm$^{-1}$ (84 (71; 97) % predicted). Peak systemic arterial partial pressure of O$_2$ ($PaO_2$) and CO$_2$ ($PaCO_2$) were 91 (70; 99) and 39 (35; 41) mmHg, respectively. Arterial lactate was 5.6 (4.7; 7.0) mmol·L$^{-1}$ at peak exercise.

Functional characteristics of patients classified by GOLD scaling system are shown in Table 1. Static hyperinflation significantly decreased incrementally from stage I to stage III–IV among baseline pulmonary function parameters (Table 1). Tables 2–4 (main features of CPET, ventilatory and cardiovascular response details, respectively) display all results and significant differences of medians of exercise parameters between each group (GOLD stage I, stage II and stage III–IV) after adjustments. Peak $V'_O$ (% of predicted values) was not significantly different between GOLD stages (Table 2). At peak exercise (Table 3), EELV (% TLC), $V'_D/V'_T$(%) and $PaCO_2$ significantly increased incrementally with patient’s COPD severity. $IC_{dyn}$ significantly decreased incrementally with patient’s COPD severity (Table 3).

The nonlinear procedure established between $IC_{dyn}$ change and CMI (Figure 1A) or $HR_{max}$ (Figure 1B) has converged to broken-line models. The best fit, which was defined
by the smallest AIC, allowed us to obtain the values of the following knots $IC_{dyn}$ (mean ± standard error): −0.28±0.1 L and −0.39±0.08 L, respectively. The middle of the overlap area allowed us to determine the DH threshold with $IC_{dyn}$ change equal to −0.34 L.

The prevalence of DH was higher in GOLD III–IV patients than in GOLD I–II patients (Table 5). Patients with lung hyperinflation had more CI than patients without DH (Table 5). CI status was not related to GOLD score ($P=0.1$).

The logistic regression that analyzed the association between CI (outcome) and DH showed a strong relationship (OR [confidence interval 95%]) 20 [4.4–91.9] that was confirmed by multivariate analysis taking into account the following covariates: age, BMI, TLC, CI/TLC, RV/TLC and GOLD stage (Table 6).

### Discussion

A new finding of this study is that lung hyperinflation in COPD patients is associated with impaired metabolic-chronotropic relationship, so-called CI, which may present as a limiting factor of exercise tolerance.

In our study, both static and dynamic lung volume measurements were performed to assess lung hyperinflation in COPD patients. Among baseline pulmonary function parameters, we used IC/TLC ratio as a static hyperinflation-derived variable.

### Table 1 Subject characteristics

| GOLD stage | Stage I (n=6) | Stage II (n=26) | Stage III-IV (n=15) | P-value |
|------------|--------------|-----------------|---------------------|---------|
| Age, years | 53.5 (49; 56) | 60 (54; 64)$^i$ | 49 (44; 56)$^i$ | 0.031 |
| BMI, kg·m$^{-2}$ | 26.0 (23.8; 26.4) | 27.8 (22.8; 30.7) | 21.9 (18.9; 29.1) | 0.224 |
| Gender, M/F | 4/2 | 22/4 | 7/8 | 0.028 |
| Smoking status, % current | 50 | 40 | 20 | 0.238 |
| Smoking, pack-year | 30 (30; 40) | 27.5 (16.5; 40) | 42.3 (25; 61) | 0.279 |

### Table 2 Cardiopulmonary exercise testing (peak values, except AT)

| GOLD stage | Stage I (n=6) | Stage II (n=26) | Stage III-IV (n=15) | P-value |
|------------|--------------|-----------------|---------------------|---------|
| Workload, W | 97.5 (95; 150)$^*$ | 90 (80; 100)$^i$ | 65 (60; 85)$^*$ | <0.001 |
| $V'\text{O}_2$, ml·kg$^{-1}$·min$^{-1}$ | 24.3 (23.6; 25.2)$^*$ | 18.5 (15.5; 21.8) | 17.5 (15.4; 19.1)$^*$ | 0.035 |
| $V'\text{O}_2$, % predicted | 77.4 (62.8; 80.9) | 70.0 (55.0; 80.0) | 64.0 (61.0; 68.0) | 0.215 |
| AT $V'\text{O}_2$, ml·kg$^{-1}$·min$^{-1}$ | 16.0 (15.0; 16.6)$^*$ | 12.1 (10.6; 14.1)$^*$ | 12.0 (11.0; 13.4)$^*$ | 0.033 |
| RER | 1.2 (1.0; 1.3) | 1.2 (1.1; 1.2) | 1.2 (1.1; 1.2) | 0.859 |
| Arterial lactate, mmol·L$^{-1}$ | 7.6 (5.7; 9.2) | 5.7 (4.8; 7.3) | 5.5 (4.3; 6.4) | 0.036 |
| Borg dyspnea score | 4 (3; 7) | 4 (3; 5) | 3 (3; 5) | 0.865 |
| Borg leg effort score | 4 (4; 7) | 4 (3; 5) | 3 (2; 5) | 0.314 |
reflecting mechanical inspiratory constraint.\(^1\)\(^-\)\(^3\) We found that over a wide range of airflow, IC/TLC decreased incrementally with FEV\(_1\)/FVC obstruction. Such relationship was also observed with RV/TLC, which increased incrementally with FEV\(_1\)/FVC. Next, we established exercise-induced DH by measuring IC\(_{\text{dyn}}\),\(^1\)\(^-\)\(^3\) IC\(_{\text{psy}}\), significantly decreased incrementally with patient’s GOLD score severity. DH was associated with increased \(V^*\), constraint as \(V^*/\text{FEV}_1\) inflection point expressed as peak \(V^*\), percent was decreased incrementally with patient’s COPD severity. DH was accompanied with poor cardiovascular response, which was evaluated in our study by noninvasive surrogate markers, such as OUES and \(O_2\) pulse.\(^5\)\(^-\)\(^7\) \(O_2\) pulse, a noninvasive measure of stroke volume, requires assumption that the arteriovenous \(O_2\) content difference remains constant during exercise. Physiologically, arterial \(O_2\) content can be altered by hemoglobin availability, arterial blood oxygenation and peripheral \(O_2\) extraction.\(^11\) In our series of COPD patients, hemoglobin concentration and calculated arterial content were within the normal ranges. Furthermore, whether \(O_2\) extraction was normal or reduced in our patients, these changes may not account for \(O_2\) pulse reduction, since a lower \(O_2\) extraction would actually increase \(O_2\) pulse.\(^5\)\(^-\)\(^10\)

Beside the negative effects of abnormal ventilatory mechanics on cardiac stroke volume, CI can also prevent the

### Table 3 Ventilatory response during submaximal exercise (peak values, except \(V^*/\text{FEV}_1\) inflection point)

| GOLD stage | Stage I | Stage II | Stage III–IV | P-value |
|------------|---------|----------|--------------|--------|
| Sample size | n=6 | n=26 | n=15 | |
| \(f^*\), breaths-min\(^{-1}\) | 31 (23; 41) | 31 (27; 38) | 34 (30; 38) | 0.655 |
| \(V^*_1\), L | 2.3 (1.8; 3.3)* | 1.8 (1.6; 2.0)# | 1.5 (1.1; 1.6)* | 0.001 |
| \(V^*_1/\text{FEV}_1\), % | 74.9 (59.5; 91.0)# | 83.6 (74.6; 91.0)# | 105.0 (85.6; 117.2)* | 0.003 |
| \(V^*_1/\text{FVC}\), % | 49.5 (40.7; 57.3) | 48.4 (45.2; 51.1) | 46.3 (38.5; 50.2) | 0.649 |
| \(V^*_1\), L-min\(^{-1}\) | 76.5 (64; 88)* | 54.5 (48; 64)* # | 48 (37; 53)* # | <0.0001 |
| \(V^*_1\) reserve, % predicted | 33.9 (11.7; 44.9)* | 28.0 (21.8; 34.4)* | 2.7 (< 10.5; 16.6)* | <0.0001 |
| \(V^*_1/\text{FEV}_1\) inflection point, % peak \(V^*_1\) | 52.5 (46; 61)* | 40 (32; 50)*# | 30 (26; 32)*# | <0.0001 |
| IC\(_{\text{psy}}\), L | -0.08 (< 0.14; 0.11)* | -0.38 (< 0.52; 0)* | -0.67 (< 0.95; -0.35)* | <0.0001 |
| EELV/TLC, % | 53 (49; 58)* | 61 (54; 70)* | 70 (68; 79)* | <0.0001 |

**Notes:** Data are presented as median (interquartile range). *#Significant difference between groups. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; \(f^*\), breathing frequency; \(V^*_1\), tidal volume; \(V^*_1/\text{FEV}_1\), forced expiratory volume in the first second; FVC, forced expiratory vital capacity; \(V^*_1\), minute ventilation; IC\(_{\text{psy}}\), dynamic inspiratory capacity; EELV, end-expiratory lung volume; TLC, total lung capacity; \(V^*_1\), dead volume; Pa\(_{O_2}\), arterial partial pressure of oxygen; Pa\(_{CO_2}\), arterial partial pressure of carbon dioxide.

### Table 4 Cardiovascular response during submaximal exercise (peak values, except recovery)

| GOLD stage | Stage I | Stage II | Stage III–IV | P-value |
|------------|---------|----------|--------------|--------|
| Sample size | n=6 | n=26 | n=15 | |
| HR, beat-min\(^{-1}\) | 149 (142; 162) | 130 (113; 150) | 133 (122; 140) | 0.074 |
| HR, peak-rest, beat-min\(^{-1}\) | 60 (54; 71) | 42.5 (32; 67) | 42 (28; 61) | 0.102 |
| HR, cov, % | 88.2 (83.3; 94.7)* | 79.2 (73.4; 90.6) | 78.8 (70.7; 83.2)* | 0.042 |
| HR reserve use, % | 76.3 (67.5; 87.3)* | 55.0 (41.3; 80.6) | 52.5 (42.6; 63.8)* | 0.032 |
| Chronotropic-metabolic index | 0.68 (0.61; 0.73)* | 0.58 (0.47; 0.75) | 0.47 (0.39; 0.60)* | 0.027 |
| \(O_2\) pulse, mL-beat\(^{-1}\) | 11.7 (10.5; 12.4)* | 10.8 (10.1; 13.9)* | 8.3 (7.3; 9.7)* | <0.0001 |
| \(O_2\) pulse, % predicted | 95.5 (88.0; 104.0)* | 86.0 (74.0; 90.9)* | 77.0 (65.0; 82.0)*# | 0.005 |
| OUES, mL-min\(^{-1}\) | 1 548 (1 344; 1 988) | 1 701 (1 467; 1 988) | 1 321 (1 138; 1 937) | 0.188 |
| \(V^*/\text{CO}_2\) slope | 26.1 (23.8; 30.3) | 30.2 (26.9; 33.5) | 32.0 (29.0; 37.4) | 0.079 |
| Mean arterial pressure, mmHg | 125.3 (120.0; 133.0) | 123.7 (103.5; 135.2) | 117.0 (111.7; 125.0) | 0.537 |
| Double product, mmHg-beat-min\(^{-1}\) | 29 523 (28 120; 31 266)* | 25 619 (23 471; 29 539)* | 20 295 (19 380; 24 024)*# | <0.0001 |

**Notes:** Data are presented as median (interquartile range). *#Significant difference between groups. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, heart rate; HR, cov, age predicted maximum heart rate; min, minute; \(O_2\), oxygen; OUES, oxygen uptake efficiency slope; \(V^*_1\), minute ventilation; \(\text{CO}_2\), carbon dioxide output.
cardiovascular system from reaching its physiological limits before maximal exercise. In healthy humans, HR increases virtually instantaneously upon the initiation of exercise. Involvement of a reduction in cardiac parasympathetic activity has been demonstrated in human studies showing that atropine can significantly attenuate the initial increase in HR in a variety of exercise conditions. In contrast, the magnitude of HR increase at the onset of exercise is not diminished by prior β-adrenergic blockade, implying a minimal influence of sympathetic activity at this time. Thereafter, there is an approximately linear relationship between HR and \( V_{O_2} \) during incremental exercise. At moderate-to-elevated exercise intensities β-adrenergic blockade significantly attenuates the size of the HR response, thus suggesting a key role for heightened sympathetic nervous system and elevated catecholamine levels in the circulation. At immediate cessation of exercise, HR abruptly declines, which is typically followed by a more gradual decline of HR over minutes depending on exercise conditions. Initial HR recovery is related to rapid restoration of cardiac parasympathetic activity, since it is virtually abolished by atropine administration, but unaffected by β-adrenergic blockade.

Blunted HR response is the primary cause of or a significant contributor to severe, symptomatic exercise intolerance in heart failure patients. Mechanisms of CI have been related to overstimulation of the sympathetic system, which induces downregulation of β-receptors and their desensitization in the presence of increased circulating catecholamine levels. In COPD patients, a striking elevation of sympathetic tone has been demonstrated and might thus provide a link between COPD and CI. Hypoxemia, chemoreflexes, impaired baroreflex sensitivity, muscle ergoreflex and lung hyperinflation are important factors contributing to neurohumoral activation in COPD. In normal subjects, sympathetic nerve firings are synchronized with central inspiratory motor activity and increase in lung volume during inspiration activates pulmonary vagal afferents that in turn inhibit sympathetic nerve discharge. The relative magnitude of these two opposing mechanisms determines the net effect of respiratory modulation of sympathetic nerve activity, which is in favor of sympathetic activation in COPD patients.

Although lung hyperinflation may induce sympathetic overactivation in COPD patients, whether DH would lead to CI during submaximal exercise has not been previously tested. In normal subjects, CI has been most commonly diagnosed when HR fails to reach 80%–85% of the HR

\[ \text{max} \]

However, before one concludes that a patient has CI, it is important to consider the patient’s level of effort. Whether attenuated HR in response to incremental exercise is related to low effort level or CI represents a major issue in this context. Hence, in order to more objectively evaluate CI, the relationship between HR and \( V_{O_2} \) during exercise should be measured. In this approach, the metabolic-chronotropic relationship is calculated from the ratio of the HR reserve to the metabolic reserve during submaximal exercise. If the assumption on which percentage of HR reserve equal \( V_{O_2} \) reserve is achieved in normal adults, a relationship slope less than 0.75–0.8 is considered indicative of CI in chronic heart disease patients.

In our study, this metabolic-chronotropic relationship approach allowed us to define an association between CI and DH, which was further characterized by broken-line trend analysis with a reduced IC

\[ \text{dyn} \]

of 0.34 L as a threshold level for CI.

In conclusion, we have shown that CI evaluated by the metabolic-chronotropic relationship is highly prevalent in a cohort of COPD patients. Adding evaluation of CI to standard pulmonary function parameters at rest and during incremental exercise allows to determine the level of lung hyperinflation as a potential mechanism of attenuated HR response.

**Acknowledgment**

The authors thank all of the staff of the Pulmonary Functional Tests Department for their help in this work.

---

**Table 5** Relationships between dynamic hyperinflation, GOLD stage and chronotropic incompetence

| Group | No hyperinflation | Hyperinflation | P-value** |
|-------|-------------------|---------------|-----------|
| GOLD | 18                | 14            | 0.019     |
| I–II | 3                 | 12            |           |
| III–IV | 14.3            | 76.9          | <0.0001   |

**Notes:** *Defined by an IC

\[ \text{dyn} \] \leq -0.34 L. *P*-values obtained by Fisher exact test. Bold values represent the significant results.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; IC

\[ \text{dyn} \], dynamic inspiratory capacity.

**Table 6** Multivariate analysis of chronotropic incompetence

| Variables | OR (95% confidence interval) |
|-----------|-----------------------------|
| Dynamic hyperinflation status | 25 (3.5–191.6)* |
| Age       | 1.094 (1.008–1.187)* |
| BMI       | 0.952 (0.826–1.098) |
| TLC       | 0.676 (0.342–1.336) |
| IC/TLC    | 0.956 (0.849–1.076) |
| RV/TLC    | 1.004 (0.970–1.039) |
| GOLD stage | 1.056 (0.988–12.634) |

**Notes:** *P*-values <0.05. Bold values represent the significant results.

**Abbreviations:** OR, odds ratio; BMI, body mass index; TLC, total lung capacity; IC, inspiratory capacity; RV, residual volume; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Author contributions
All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

Abbreviations
ACE inhibitor, angiotensin-converting-enzyme inhibitor; AIC, Akaike information criterion; AT, anaerobic threshold; ATS/ACCP, American Thoracic Society/American College of Chest Physicians; BMI, body mass index; Cl, chronotropic incompetence; CMI, chronotropic-metabolic index; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise testing; DH, dynamic hyperinflation; $D_{dyn}$, diffusing capacity of the lung for carbon monoxide; EELV, end-expiratory lung volume; FEV$_1$, forced expiratory volume in the first second; FRC, functional residual capacity; FVC, forced expiratory vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, heart rate; HR$_{max}$, age predicted maximum heart rate; IC, inspiratory capacity; IC$_{max}$, dynamic inspiratory capacity; IQR, interquartile ranges; MVV, maximal voluntary ventilation; $O_2$ pulse, peak oxygen pulse; OUES, oxygen uptake efficiency slope; $P_a$, arterial partial pressure; PAP, pulmonary artery pressure; RER, respiratory exchange ratio; RV, residual volume; TLC, total lung capacity; $V^*O_2$, carbon dioxide output; $V^*v$, minute ventilation; $V^*O_2$, oxygen uptake; $V^*p$, death volume; $V^*t$, tidal volume.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:187–201.
2. Guenette JA, Webb KA, O’Donnell DE. Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD? Eur Respir J. 2012;40(2):322–329.
3. Langer D, Ciavaglia CE, Neder JA, Webb KA, O’Donnell DE. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med. 2014;8(6):731–749.
4. Vogiatzis I, Zakynthinos S. Factors limiting exercise tolerance in chronic lung diseases. Compr Physiol. 2012;2(3):1879–1817.
5. Chuang ML, Huang SF, Su CH. Cardiovascular and respiratory dysfunction in chronic obstructive pulmonary disease complicated by impaired peripheral oxygenation. Int J Chron Obstruct Pulmon Dis. 2015;10:329–337.
6. Tzani P, Aiello M, Elia D, et al. Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients. Respir Res. 2011;12:150.
7. Visca D, Aiello M, Chetta A. Cardiovascular function in pulmonary embolism. Biomed Res Int. 2013;2013:184678.
8. Teopompi E, Tzani P, Aiello M, et al. Fat-free mass depletion is associated with poor exercise capacity irrespective of dynamic hyperinflation in COPD patients. Respir Care. 2014;59(5):718–725.
9. Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008;32(5):1275–1282.
10. Lammi MR, Ciccolella D, Marchetti N, Kohler M, Criner GJ. Increased oxygen pulse after lung volume reduction surgery is associated with reduced dynamic hyperinflation. Eur Respir J. 2012;40(4):837–843.
11. Brubaker PH, Kitzman DW. Chronotropic incompetence: causes, consequences, and management. Circulation. 2011;123(9):1010–1020.
12. Fisher JP, Young CN, Fadel PJ. Autonomic adjustments to exercise in humans. Compr Physiol. 2015;5(2):475–512.
13. Coote JH. Recovery of heart rate following intense dynamic exercise. Exp Physiol. 2010;95(3):431–440.
14. Wilkoff BL, Miller RE. Exercise testing for chronotropic assessment. Cardiol Clin. 1992;10(4):705–717.
15. Benes J, Kotrc M, Borlaug BA, et al. Resting heart rate and heart rate reserve in advanced heart failure have distinct pathophysiologic correlates and prognostic impact: a prospective pilot study. JACC Heart Fail. 2013;1(3):259–266.
16. Wang J, Fang F, Yip GW, et al. Importance of chronotropic response and left ventricular long-axis function for exercise performance in patients with heart failure and preserved ejection fraction. Int J Cardiol. 2016;202:339–343.
17. Bristow MR, Hersberger RE, Port JD, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. 1990;82(2 Suppl):112–125.
18. Colucci WS, Ribeiro JP, Rocco MB, et al. Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization. Circulation. 1989;80(2):314–323.
19. Breskovic T, Steinback CD, Salmanpour A, Shoemaker JK, Dujic Z. Recruitment pattern of sympathetic neurons during breath-holding at different lung volumes in apnea divers and controls. Auton Neurosci. 2011;164(1–2):74–81.
20. Dempsey JA, Sheel AW, St Croix CM, Morgan BJ. Respiratory influences on sympathetic vasomotor outflow in humans. Respir Physiol Neurobiol. 2002;130(1):3–20.
21. Andreas S, Auker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005;128(5):3618–3624.
22. van Gestel AJ, Kohler M, Clarenbach CF. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Discov Med. 2012;14(79):359–368.
23. Armstrong HF, Gonzalez-Costello J, Jorde UP, et al. The effect of lung volume reduction surgery on chronotropic incompetence. Respir Med. 2012;106(10):1389–1395.
24. Gupta M, Bansal V, Chhabra SK. Abnormal heart rate recovery and chronotropic incompetence on exercise in chronic obstructive pulmonary disease (COPD). Chron Respir Dis. 2013;10(3):117–126.
25. González-Costello J, Armstrong HF, Jorde UP, et al. Chronotropic incompetence predicts mortality in severe obstructive pulmonary disease. Respir Physiol Neurobiol. 2013;188(2):113–118.
26. Gupta N, Pinto LM, Morogan A, Bourbeau J. The COPD assessment test: a systematic review. Eur Respir J. 2014;44(4):873–884.
27. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338.
28. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211–277.
29. Hollenberg M, Tager IB. Oxygen uptake efficiency slope: an index of exercise performance and cardiopulmonary reserve requiring only submaximal exercise. J Am Coll Cardiol. 2000;36(1):194–201.
30. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2007;176(6):532–555.

31. Robbins KR, Saxton AM, Southern LL. Estimation of nutrient requirements using broken-line regression analysis. *J Anim Sci*. 2006;84 Suppl: E155–E165.

32. Nève V, Edmé JL, Matran R. Earlier decline in sniff nasal inspiratory pressure than peak expiratory flow in children with Duchenne muscular dystrophy. *Eur Respir J*. 2014;44(5):1361–1363.

33. Whipp BJ, Higgenbotham MB, Cobb FC. Estimating exercise stroke volume from asymptotic oxygen pulse in humans. *J Appl Physiol (1985)*. 1996;81(6):2674–2679.

34. Robinson BF, Epstein SE, Beiser GD, Braunwald E. Control of heart rate by the autonomic nervous system. Studies in man on the inter-relation between baroreceptor mechanisms and exercise. *Circ Res*. 1966;19(2):400–411.

35. Fagraeus L, Linnarsson D. Autonomic origin of heart rate fluctuations at the onset of muscular exercise. *J Appl Physiol*. 1976;40(5):679–682.

36. Maciel BC, Gallo L Jr, Marin Neto JA, Lima Filho EC, Martins LE. Autonomic nervous control of the heart rate during dynamic exercise in normal man. *Clin Sci (Lond)*. 1986;71(4):457–460.

37. Imai K, Sato H, Hori M, et al. Vagal mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. *J Am Coll Cardiol*. 1994;24(6):1529–1535.

38. Jouett NP, Watenpaugh DE, Dunlap ME, Smith ML. Interactive effects of hypoxia, hypercapnia and lung volume on sympathetic nerve activity in humans. *Exp Physiol*. 2015;100(9):1018–1029.

39. da Cunha FA, Farinatti Pde T, Midgley AW. Methodological and practical application issues in exercise prescription using the heart rate reserve and oxygen uptake reserve methods. *J Sci Med Sport*. 2011;14(1):46–57.

40. Mezzani A, Corra U, Giordano A, Cafagna M, Adriano EP, Giannuzzi P. Unreliability of the %VO2 reserve versus %heart rate reserve relationship for aerobic effort relative intensity assessment in chronic heart failure patients on or off beta-blocking therapy. *Eur J Cardiovasc Prev Rehabil*. 2007;14(1):92–98.